Evidence map›Paper›PMID 25849301›Full record

Trial reportPloS one2015

The RGS2 (-391, C>G) genetic variation correlates to antihypertensive drug responses in Chinese patients with essential hypertension.

Fazhong He, Jianquan Luo, Zhitao Zhang, Zhiying Luo, Lan Fan, Yijing He, Jiagen Wen, Dingilang Zhu, Jinping Gao, Yan Wang and 4 more

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Polytropic Influence ofFrontiers in pharmacology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Fazhong HeDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R.C; Institute of Clinical Pharmacology, Central South University, Changsha, P.R.C; Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R.C.
Jianquan LuoDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R.C; Institute of Clinical Pharmacology, Central South University, Changsha, P.R.C; Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R.C.
Zhitao ZhangSecond uropoiesis surgical department in Han Dan Central Hospital, Handan, P.R.C.
Zhiying LuoDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R.C; Institute of Clinical Pharmacology, Central South University, Changsha, P.R.C; Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R.C.
Lan FanDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R.C; Institute of Clinical Pharmacology, Central South University, Changsha, P.R.C; Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R.C.
Yijing HeDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R.C; Institute of Clinical Pharmacology, Central South University, Changsha, P.R.C; Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R.C.
Jiagen WenDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R.C; Institute of Clinical Pharmacology, Central South University, Changsha, P.R.C; Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R.C.
Dingilang ZhuShanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P.R.C.
Jinping GaoShanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P.R.C.
Yan WangShanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P.R.C.
Yuesheng QianShanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P.R.C.
Honghao ZhouDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R.C; Institute of Clinical Pharmacology, Central South University, Changsha, P.R.C; Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R.C.
Xiaoping ChenDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R.C; Institute of Clinical Pharmacology, Central South University, Changsha, P.R.C; Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R.C.
Wei ZhangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R.C; Institute of Clinical Pharmacology, Central South University, Changsha, P.R.C; Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R.C.
Xiangya Hospital Central South University · CNCentral South University · CNShanghai Institute of Hypertension · CNHandan College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveRegulators of G-protein signaling protein 2 (RGS2) play an irreplaceable role in the control of normal blood pressure (BP). One RGS2 (-391, C>G) genetic variation markedly changes its mRNA expression levels. This study explored the relationship between this genetic variation and the responses to antihypertensive drugs in Chinese patients with essential hypertension.

methodsGenetic variations of RGS2 were successfully identified in 367 specimens using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assays. All patients were treated with conventional doses of antihypertensives after a 2-week run-in period and followed-up according to our protocol. A general linear model multivariate analysis of variance (ANOVA) was used for the data analysis.

resultsA significant difference in the mean systolic BP change was observed between RGS2 (-391, C>G) CC/CG (n = 82) and GG (n = 38) genotype carriers (-13.6 vs. -19.9 mmHg, P = 0.043) who were treated with candesartan, irbesartan or imidapril at the end of 6 weeks. In addition, the patients' BP responses to α,β-adrenergic receptor blockers exhibited an age-specific association with the RGS2 (-391, C>G) genetic variation at the end of 4 weeks.

conclusionThe RGS2 (-391, C>G) genetic polymorphism may serve as a biomarker to predict a patient's response to antihypertensive drug therapy, but future studies need to confirm this.

Indexed as

HypertensionModels, BiologicalPolymorphism, Restriction Fragment LengthAdultAgedAged, 80 and overAntihypertensive AgentsAsian PeopleChinaEssential HypertensionFemaleHumansMaleMiddle AgedRGS ProteinsAntihypertensive AgentsRGS2 protein, humanRGS Proteins

Identifiers

PMID25849301
PMCPMC4388730
OpenAlexW1975502924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.